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endpoints included progression-free survival, overall sur-
vival, and toxicity.
Results From March 2007 to October 2010, 46 patients 
were enrolled in this phase II study. the median age was 
64 years (range 32–85). a total of 391 (median 7.5, range 
1–29) cycles were delivered. among the 41 patients evalu-
able for tumor response, 9 showed partial response and 25 
had stable disease. the overall response rates of the evalu-
able and intent-to-treat (Itt) populations were 22 % (95 % 
CI 10–42 %) and 20 % (95 % CI 9–34 %), respectively. 
In the Itt analysis, the progression-free survival and over-
all survival were 5.6 months (95 % CI 4.1–6.3 months) 
Abstract 
Purpose We evaluated the safety and efficacy of biweekly 
capecitabine in combination with oxaliplatin in previously 
untreated patients with locally advanced or metastatic gas-
tric cancer.
Methods Patients received oral capecitabine 1,000 mg/m2 
twice daily on days 1–10 plus oxaliplatin 85 mg/m2 as a 2-h 
intravenous infusion on day 1, every 2 weeks (XelOX). 
the primary endpoint was overall response rate. Secondary 
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and 8.0 months (95 % CI 6.3–10.1 months), respectively. 
the most common hematological toxicities were throm-
bocytopenia (35 %) and leucopenia (34 %), whereas the 
most common non-hematological toxicities were neu-
ropathy (35 %), fatigue (33 %), diarrhea (27 %), vomiting 
(26 %), and hand-foot syndrome (25 %). Major grade 3–4 
toxicities were anemia (11 %), diarrhea (9 %), and hand-
foot syndrome (7 %). no patient died of treatment-related 
toxicities.
Conclusions although the biweekly XelOX regimen 
failed its primary response rate endpoint, it showed modest 
efficacy and an acceptable safety profile in the treatment of 
advanced gastric cancer.
Keywords gastric cancer · Phase II study · Biweekly 
XelOX · Capecitabine · Oxaliplatin
Introduction
gastric cancer is the fourth most common and the second 
leading cause of cancer deaths in the world. according to 
global estimates, gastric cancer was newly diagnosed in 
approximately 989,600 people and caused approximately 
738,000 deaths in 2008, with the highest rates occurring in 
eastern asia [1]. although early diagnosis of gastric cancer 
has improved, most patients still show locally advanced or 
metastatic disease upon diagnosis. even if surgery is per-
formed with a curative intent, 60 % of patients with resect-
able tumors will ultimately relapse [2].
It has been demonstrated that combination chemother-
apy regimens in advanced gastric cancer improve overall 
survival and progression-free survival of patients and main-
tain quality of life [3]. 5-Fluorouracil (5-FU) in combina-
tion with cisplatin is a generally accepted standard treat-
ment option for advanced gastric cancer patients [4–8]. 
the combination regimen of 5-FU and cisplatin achieves 
overall response rates of 20–51 %, median progression-free 
survival of 3.3–6.5 months, and median overall survival of 
7–11 months [4–8]. nevertheless, the required weekly 24-h 
intravenous infusion of 5-FU is inconvenient, cumbersome, 
and associated with the risk of infection and thrombosis.
Capecitabine, a novel oral fluoropyrimidine designed 
to mimic the continuous infusion of 5-FU, is administered 
orally. after oral administration, it is efficiently absorbed 
from the gastrointestinal tract and metabolized primarily 
in the liver. Capecitabine is then sequentially converted to 
the cytotoxic 5-FU moiety in tumor tissues by the enzyme 
thymidine phosphorylase, which shows significantly higher 
activities in tumors than in normal tissues [9, 10]. In sev-
eral phase II studies, capecitabine has shown good response 
rates in advanced gastric cancer patients when provided as 
monotherapy or in combination with cisplatin, achieving 
response rates of 19–34 and 55 %, respectively [11–14]. 
Oral fluoropyrimidine administration can eliminate the 
inconvenience and the risks (i.e., venous thrombosis and 
sepsis) associated with the infusion of 5-FU. Furthermore, 
capecitabine showed non-inferior effects compared with 
5-FU in gastric cancer patients [15].
Oxaliplatin, initially developed to treat colorectal cancer, 
is an alkylating agent that forms adducts between two adja-
cent guanines or a guanine and an adenine residue, leading 
to the inhibition of Dna replication [16]. Compared with 
cisplatin, oxaliplatin appears to have a more favorable tol-
erability profile. In particular, renal toxicity and ototoxic-
ity are not associated with oxaliplatin, but are commonly 
encountered during cisplatin therapy [17]. the dose-limit-
ing toxicity of oxaliplatin is a cumulative sensory periph-
eral neuropathy. In randomized phase III trials, oxaliplatin 
was non-inferior to cisplatin in the treatment of esophago-
gastric cancer [18, 19].
triweekly oxaliplatin plus oral capecitabine has become 
a new standard for the treatment of advanced gastric can-
cer [20–25], achieving response rates of 42–63 % in pub-
lished phase II studies [20–24]. these results warrant fur-
ther investigation into this drug combination in patients 
with gastrointestinal malignancies. a biweekly regimen of 
the same chemotherapy combination has been shown to be 
effective in metastatic colorectal cancer [26], but biweekly 
data are currently not available for advanced gastric cancer. 
the aim of this study was to demonstrate the efficacy and 
safety of a biweekly regimen of capecitabine in combina-
tion with oxaliplatin in previously untreated patients with 
locally advanced or metastatic gastric cancer.
Patients and methods
Study design
this is a multicenter study to investigate the safety and effi-
cacy profiles of biweekly capecitabine (Xeloda®) in com-
bination with oxaliplatin (eloxatin®) as first-line therapy 
in patients with locally advanced or metastatic gastric can-
cer. the primary objective was to investigate the objective 
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response rate of capecitabine plus oxaliplatin treatment in 
previously untreated locally advanced or metastatic gastric 
cancer patients. Secondary objectives included progression-
free survival, duration of response, overall survival (OS), 
and safety profiles. the study protocol was approved by 
the medical ethics committees of all participating centers 
and was registered as Clinicaltrial.gov (nCt00436241). 
Signed informed consents were obtained from all patients.
Patients
Inclusion criteria for this study were as follows: histologi-
cally confirmed gastric adenocarcinoma with unresectable 
locally advanced or metastatic disease; at least one, non-
irradiated, measurable lesion according to the response 
evaluation Criteria in Solid tumors (reCISt) [27]; 
18 years of age or older; calculated creatinine clearance 
≥50 ml/min using the Cockroft–gault formula; and east-
ern Cooperative Oncology group (eCOg) performance 
status ≤1.
Patients who fell under any of the following criteria 
were excluded from the study: previous cytotoxic chemo-
therapy (except given as adjuvant or neoadjuvant treat-
ment completed at least 6 months prior to enrollment); 
organ allografts; clinically significant cardiac disease or 
myocardial infarction within the last 12 months; evidence 
of CnS metastases; history of another malignancy within 
the last five years except for cured basal cell carcinoma of 
the skin or cured carcinoma in situ of the uterine cervix; 
radiotherapy within 4 weeks of treatment start; major sur-
gery within 4 weeks of the start of the treatment, without 
complete recovery; serious uncontrolled intercurrent infec-
tions; lack of physical integrity of the upper gastrointestinal 
tract or malabsorption syndrome; abnormal audiogram or 
auditory abnormality; significant or uncontrolled gastroin-
testinal bleeding; the following laboratory values: neutro-
phils ≤1.5 × 109/l; platelet count <100 × 109/l; serum 
bilirubin ≥1.5 × upper normal limit; alanine aminotrans-
ferase or aspartate aminotransferase >2.5 × upper normal 
limit or >5 × upper normal limit in the case of liver metas-
tases; alkaline phosphatase >2.5 × upper normal limit or 
>5 × upper normal limit in the case of liver metastases or 
>10 × upper normal limit in the case of bone disease.
treatment schedule
Capecitabine (1,000 mg/m2 twice daily, days 1–10, followed 
by four days of rest period) plus oxaliplatin (85 mg/m2 
as a 2-h intravenous infusion on day 1) were adminis-
tered in two-week cycles. Protocol treatment was discon-
tinued for patients with clearly documented progressive 
disease (PD) at any time due to insufficient therapeutic 
response. Patients who tolerated treatment and showed 
either complete response (Cr), partial response (Pr), or 
stable disease (SD) continued to be treated and followed 
until disease progression.
Dose modification for adverse events
the intensity of clinical adverse events was graded accord-
ing to the national Cancer Institute (nCI) Common termi-
nology Criteria for adverse events v3.0 (CtCae). Dose 
modifications were based on hematological and non-hema-
tological toxicities.
For hematological toxicities, dose modifications were 
based on hematological parameters at the start of a treat-
ment cycle. administration of capecitabine was interrupted 
during a treatment cycle if a grade 3 or 4 hematological 
toxicity developed. the next treatment cycle could only 
start if hematological toxicity has recovered to grade ≤1. 
no dose reduction or interruption was required for anemia 
(non-hemolytic) as it could be satisfactorily managed by 
transfusions.
For non-hematological toxicities of capecitabine, if a 
grade 2 or 3 adverse event occurred, capecitabine was inter-
rupted immediately; if a grade 4 non-hematological toxic-
ity occurred, treatment was discontinued unless the inves-
tigator considered it to be in the best interest of the patient 
to continue at 50 % of the original dose, once toxicity has 
resolved to grade 0–1. the next treatment cycle could only 
start if non-hematological toxicity has recovered to grade 
≤1. Capecitabine dose was reduced by 25 % for patients 
experiencing a second occurrence of a given grade 2 or any 
grade 3 event. the capecitabine dose was reduced by 50 % 
for patients who experienced a third occurrence of a given 
grade 2 or a second occurrence of a given grade 3 event. If 
the same toxicity occurred for a fourth time at grade 2 or a 
third time at grade 3, treatment was discontinued.
For grade <3 non-hematological toxicities of oxaliplatin, 
management was symptomatic, if possible. For grade ≥3 
non-hematological adverse events, oxaliplatin was withheld 
for a maximum of 4 weeks until toxicities were resolved. 
after patients recovered from toxicity grade 3–2 or less, 
the dose of oxaliplatin was reduced to 65 mg/m2 in sub-
sequent cycles. In case of no resolution to grade 2 or less 
after a maximum of 4 weeks from the planned date of the 
next cycle, oxaliplatin treatment was discontinued. In case 
of grade 4 toxicity, patients were removed from oxaliplatin 
treatment and followed until the resolution of the adverse 
event.
evaluation of efficacy and toxicities
evaluations, including the patient’s medical history, physi-
cal examination, complete blood count, blood chemistry, 
abdominal–pelvic computed tomography (Ct) scan, and 
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chest X-ray, were performed before chemotherapy. after 
starting the protocol treatment, blood chemistry and com-
plete blood count were assessed prior to the start of each 
cycle. tumor measurements were carried out after every 
3 cycles of treatment or when progression was suspected. 
Confirmation of overall response (complete or partial 
response), when applicable, was done at a minimum of 
4 weeks after the first response had been recorded. tumor 
response was evaluated according to the response evalu-
ation Criteria in Solid tumors (reCISt) [27]. toxicities 
were recorded according to the national Cancer Institute 
Common terminology Criteria grading system version 3, 
starting at the time of study entry and ending 28 days after 
the last dose of medication was administered.
Statistical methods
Simon’s two-stage optimal design was applied to calcu-
late the sample size, assuming that the minimum response 
rate of capecitabine plus oxaliplatin in the study was 29 % 
and the expected overall response rate was at least 50 %. 
Under α = 0.05 and 80 % power, the estimated total evalu-
able patient number was 38 to detect more than 15 patients 
having partial response. Considering a 10 % drop-out rate, 
the estimated enrolled patient number was 42. Progression-
free survival was measured as the duration from the date 
of starting protocol treatment to the date of first record-
ing disease progression or the date of death, whichever 
occurred first. Overall survival was measured as the dura-
tion from the date of starting protocol treatment to the date 
of death. Duration of response was measured from the first 
date when measurement criteria were met for Cr/Pr to the 
first date when recurrent or progressive disease or death 
was objectively documented. Survival was estimated by 
the Kaplan–Meier analysis. all statistics were two-sided 




Between March 2007 and november 2008, forty-six 
patients (Itt population) from ten medical centers in tai-
wan were enrolled in this study. the clinical and pathologic 
characteristics of patients are listed in table 1.
efficacy
the tumor response rates are shown in table 2. Five 
patients could not be evaluated for response due to failure 
to return for tumor measurements. among the 41 evaluable 
patients, the best tumor response was partial response (Pr) 
in 9 patients, whereas 25 patients showed stable disease and 
7 patients progressive disease. the overall response rates 
of the evaluable and intent-to-treat (Itt) populations were 
22 % (95 % CI 10–42 %) and 20 % (95 % CI 9–34 %), 
respectively, whereas the disease control rates in the cor-
responding populations were 83 % (95 % CI 68–93 %) 
and 74 % (95 % CI 59–86 %), respectively. Median time 
to tumor response was 1.4 months (range 1.2–2.8 months). 
the median duration of response was 5.1 months (95 % CI 
Table 1  Clinicopathologic features of the patients
a
 Patients could have more than one site of metastasis
Patient number (%)
total patients 46
age (years), median (range) 64 (32–85)
Sex, male/female 31/15
race
 Oriental 46 (100)
eCOg performance
 0 25 (54)
 1 21 (46)
Disease status
 locally advanced 3 (7)
 recurrence/metastasis 43 (93)
Differentiation
 Well differentiated 1 (2)
 Moderately differentiated 11 (24)
 Poorly differentiated 21 (46)
 not assessable 13 (28)
Metastatic sitea
 liver 23 (50)
 lymph nodes 20 (43)
 Peritoneum 13 (28)
 lung 6 (13)
 Bone 5 (11)
 Pleura 3 (7)
 Soft tissue 2 (4)
 Others 13 (28)
Table 2  treatment response (n = 46)
CR complete response, PR partial response
responses number of patients % of patients
Overall response rate (Cr + Pr) 9 20
 Complete response 0 0
 Partial response 9 20
Stable disease 25 54
Progressive disease 7 15
not assessable 5 11
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2.8–9.7 months). Of the 46 patients, 26 received second-
line and subsequent therapies, with a total of 47 additional 
regimens received. among them, six patients received 
monotherapy (2 UFUr, 1 capecitabine, 1 everolimus, 1 
irinotecan, and 1 paclitaxel), 9 patients received cisplatin 
plus fluoropyrimidine-based therapy, 4 patients received 
anthracycline-based therapy with various combinations of 
5-FU, cisplatin, and cyclophosphamide, 4 patients received 
taxane-based therapy, 3 patients received oxaliplatin-based 
therapy, 4 patients received irinotecan-based therapy, and 2 
patients received 5-FU plus cyclophosphamide or cetuxi-
mab. three additional patients also received mainly fluoro-
pyrimidine-based subsequent therapy.
Median follow-up time was 7.8 months (range 0.7–
35.9 months). Median progression-free survival and over-
all survival were 5.6 months (95 % CI 4.1–6.3 months) 
and 8.0 months (95 % CI 6.3–10.1 months), respectively. 
the Kaplan–Meier estimated progression-free survival and 
overall survival curves are shown in Figs. 1 and 2, respec-
tively. Overall survival at 1 year was 26.9 % and at 2 years 
was 13.4 %.
Safety
a total of 391 (median 7.5, range 1–29) cycles of chemo-
therapy were given. the median relative dose intensity was 
Fig. 1  Progression-free survival 
of the 46 patients
Fig. 2  Overall survival of the 
46 patients
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88.5 % (range 51.4–103.2 %) for capecitabine and 99.3 % 
(range 43.6–103.9 %) for oxaliplatin. In total, 82.6 % of the 
patients received more than 80 % of the intended dose of 
capecitabine, and 95.7 % received more than 80 % of the 
intended dose of oxaliplatin.
all patients were evaluated for toxicities (table 3). 
the most common hematological toxicity was thrombo-
cytopenia (33 %), but without grade 3 or 4 events. grade 
3 leucopenia was observed in 2 % of the patients. grade 
3–4 anemia developed in five patients (11 %). the most 
common non-hematological toxicities were neuropathy 
(35 %), fatigue (31 %), diarrhea (26 %), vomiting (26 %), 
and hand-foot syndrome (22 %). Major grade 3 toxicities 
were diarrhea (9 %) and hand-foot syndrome (7 %). treat-
ment was delayed in 82 cycles (21 %), and dose modifi-
cations were implemented in 13 cycles (3 %). the most 
frequent cause of treatment delays was thrombocytopenia 
(31/82; 38 %), and the major reason for dose modification 
was hand-foot syndrome (6/13; 46 %). there were no treat-
ment-related deaths.
Discussion
a combination chemotherapy regimen of 5-FU plus cis-
platin has been widely used for the treatment of advanced 
gastric cancer patients [4–8]. However, this regimen is 
inconvenient, cumbersome, and associated with the risk 
of infection and thrombosis due to the continuous 5-FU 
infusion. In addition, cisplatin has a poor tolerability, due 
mostly to its renal toxicity.
triweekly oxaliplatin plus oral capecitabine has been 
used for treating advanced gastric cancer, with response 
rates of 42–63 % and overall survival of 10.0–11.9 months 
[20–24]. In the treatment of metastatic colorectal cancer, 
biweekly oxaliplatin plus oral capecitabine has been shown 
to be as active as oxaliplatin plus intravenous 5-FU/leuco-
vorin, with similar quality of life for patients [26]. How-
ever, the efficacy and toxicities of biweekly oxaliplatin 
plus oral capecitabine in treating advanced gastric cancer 
have not been investigated so far. this is the first phase II 
trial of using biweekly oxaliplatin plus oral capecitabine in 
advanced gastric cancer.
In a multicenter open-label phase II study, oral capecit-
abine has been shown to be an active and well-tolerated 
treatment in gastric cancer patients [13]. In a phase III trial 
of capecitabine in advanced gastric cancer, it has shown a 
non-inferior effect and similar safety profile to 5-FU [15]. 
In two published phase III studies, oxaliplatin was non-
inferior to cisplatin and resulted in reduced toxicity com-
pared with cisplatin in the treatment of esophagogastric 
cancer patients [18, 19]. Based on these published articles, 
capecitabine and oxaliplatin are considered as effective as 
5-FU and cisplatin, respectively. In addition, administration 
of capecitabine is more convenient for patients than infu-
sion of 5-FU, whereas oxaliplatin is more tolerable than 
cisplatin. therefore, capecitabine and oxaliplatin are able 
to replace 5-FU and cisplatin, respectively.
the aim of this phase II study was to demonstrate the 
efficacy and safety of biweekly capecitabine in combina-
tion with oxaliplatin in previously untreated patients with 
locally advanced or metastatic gastric cancer. In our study, 
the overall response rate of Itt patients was 20 %. Median 
progression-free survival was 5.6 months, and median 
overall survival was 8.0 months. although this biweekly 
XelOX study failed to meet its primary response rate end-
point, it still showed modest efficacy in the treatment of 
advanced gastric cancer.
an important conclusion from our phase II multi-
center study was that the biweekly combination regimen 
of capecitabine and oxaliplatin had a good safety profile. 
Only 2 patients withdrew from the study because of treat-
ment-related toxicities, and there were no treatment-related 
Table 3  toxicities associated with the biweekly capecitabine plus 
oxaliplatin regimen
all numbers are percentages of the 46 patients
toxicity grade
1 2 3 4
Hematological
 leucopenia 15 17 2 0
 neutropenia 9 21 0 0
 thrombocytopenia 20 13 0 0
 anemia 4 9 9 2
gastrointestinal
 Mucositis 11 4 2 0
 anorexia 20 4 0 0
 nausea 9 4 2 0
 Vomiting 9 11 4 2
 Diarrhea 11 7 9 0
 Constipation 9 7 0 0
 abdominal pain/distension 9 9 2 0
 Weight loss 9 11 4 0
neurological
 neuropathy 26 7 2 0
 Insomnia 13 2 0 0
 Dizziness 9 0 0 0
Others
 Hand-foot syndrome 11 4 7 0
 Fatigue 28 2 0 0
 Fever 4 2 2 0
 Pitting edema 11 4 2 0
 Hypertension 2 2 2 0
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deaths. grade 3 and 4 hematological and non-hematologi-
cal adverse events were infrequent, and all toxicities were 
generally of mild to moderate intensity. the most com-
mon adverse events were thrombocytopenia (33 %), neu-
ropathy (35 %), leucopenia (35 %), neutropenia (31 %), 
fatigue (31 %), diarrhea (26 %), vomiting (26 %), anemia 
(24 %), and hand-foot syndrome (22 %). the safety profile 
reported in our trial compared favorably with other phase 
II clinical studies with triweekly combination regimens of 
capecitabine/oxaliplatin [20–24]. neuropathy, the major 
distressing toxicity of oxaliplatin, occurred in 35 % of our 
patients, which is relatively low compared to percentages 
reported in other studies (22–70 %) [20–24]. Hand-foot 
syndrome was also infrequent relative to other triweekly 
capecitabine/oxaliplatin studies (22 vs. 20–39 %) [20–24]. 
neutropenia also occurred in a lower percentage of patients 
in this study than in other reports (31 vs. 35–56 %) [20–24].
In conclusion, the combination of biweekly capecitabine 
and oxaliplatin shows modest activity and an acceptable 
safety profile. the therapeutic index of the current regimen, 
which can be helpful to advanced gastric cancer patients, 
should be further explored.
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